Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response

References

• Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat. Rev. Urol. 15(5), 271–286 (2018).
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Huang J, Alumkal JJ et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 36(24), 2492–2503 (2018).
   PubMed Web of Science ®Google Scholar
• Beltran H, Hruszkewycz A, Scher HI et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin. Cancer Res. 25(23), 6916–6924 (2019).
   PubMed Web of Science ®Google Scholar
• Drake CG, Sharma P, Gerritsen W. Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene 33(43), 5053–5064 (2014).
   PubMed Web of Science ®Google Scholar
• Bilusic M, Madan RA, Gulley JL. Immunotherapy of prostate cancer: facts and hopes. Clin. Cancer Res. 23(22), 6764–6770 (2017).
   PubMed Web of Science ®Google Scholar
• Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 10(8), 580–593 (2010).
   PubMed Web of Science ®Google Scholar
• Idorn M, Kollgaard T, Kongsted P, Sengelov L, Thor Straten P. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol. Immunother. 63(11), 1177–1187 (2014).
   PubMed Web of Science ®Google Scholar
• Jachetti E, Cancila V, Rigoni A et al. Cross-Talk between myeloid-derived suppressor cells and mast cells mediates tumor-specific immunosuppression in prostate cancer. Cancer Immunol. Res. 6(5), 552–565 (2018).
   PubMed Web of Science ®Google Scholar
• Sorrentino C, Musiani P, Pompa P, Cipollone G, Di Carlo E. Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients. Clin. Cancer Res. 17(6), 1571–1581 (2011).
   PubMed Web of Science ®Google Scholar
• Calcinotto A, Spataro C, Zagato E et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature 559(7714), 363–369 (2018).
   PubMed Web of Science ®Google Scholar
• Cioni B, Zwart W, Bergman AM. Androgen receptor moonlighting in the prostate cancer microenvironment. Endocr. Relat. Cancer 25(6), R331–R349 (2018).
   PubMed Web of Science ®Google Scholar
• Gubbels Bupp MR, Jorgensen TN. Androgen-induced immunosuppression. Front. Immunol. 9, 794 (2018).
   PubMed Web of Science ®Google Scholar
• Walecki M, Eisel F, Klug J et al. Androgen receptor modulates Foxp3 expression in CD4+CD25+Foxp3+ regulatory T-cells. Mol. Biol. Cell 26(15), 2845–2857 (2015).
   PubMed Web of Science ®Google Scholar
• Guan X, Polesso F, Wang C et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature 606(7915), 791–796 (2022).
   PubMed Web of Science ®Google Scholar
• Becerra-Diaz M, Strickland AB, Keselman A, Heller NM. Androgen and androgen receptor as enhancers of M2 macrophage polarization in allergic lung inflammation. J. Immunol. 201(10), 2923–2933 (2018).
   PubMed Web of Science ®Google Scholar
• Scalerandi MV, Peinetti N, Leimgruber C et al. Inefficient N2-like neutrophils are promoted by androgens during infection. Front. Immunol. 9, 1980 (2018).
   PubMed Web of Science ®Google Scholar
• Trigunaite A, Khan A, Der E, Song A, Varikuti S, Jorgensen TN. Gr-1(high) CD11b+ cells suppress B cell differentiation and lupus-like disease in lupus-prone male mice. Arthritis Rheum. 65(9), 2392–2402 (2013).
   PubMedGoogle Scholar
• Consiglio CR, Udartseva O, Ramsey KD, Bush C, Gollnick SO. Enzalutamide, an androgen receptor antagonist, enhances myeloid cell-mediated immune suppression and tumor progression. Cancer Immunol. Res. 8(9), 1215–1227 (2020).
   PubMed Web of Science ®Google Scholar
• Vire E, Brenner C, Deplus R et al. The polycomb group protein EZH2 directly controls DNA methylation. Nature 439(7078), 871–874 (2006).
   PubMed Web of Science ®Google Scholar
• Peng D, Kryczek I, Nagarsheth N et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527(7577), 249–253 (2015).
   PubMed Web of Science ®Google Scholar
• Wang D, Quiros J, Mahuron K et al. Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity. Cell Rep. 23(11), 3262–3274 (2018).
   PubMed Web of Science ®Google Scholar
• Goswami S, Apostolou I, Zhang J et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J. Clin. Invest. 128(9), 3813–3818 (2018).
   PubMed Web of Science ®Google Scholar
• Zhou J, Liu M, Sun H et al. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut 67(5), 931–944 (2018).
   PubMed Web of Science ®Google Scholar
• Huang S, Wang Z, Zhou J et al. EZH2 Inhibitor GSK126 suppresses antitumor immunity by driving production of myeloid-derived suppressor cells. Cancer Res. 79(8), 2009–2020 (2019).
   PubMed Web of Science ®Google Scholar
• Li C, Song J, Guo Z et al. EZH2 inhibitors suppress colorectal cancer by regulating macrophage polarization in the tumor microenvironment. Front. Immunol. 13, 857808 (2022).
   PubMed Web of Science ®Google Scholar
• Bolis M, Bossi D, Vallerga A et al. Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nat. Commun. 12(1), 7033 (2021).
   PubMed Web of Science ®Google Scholar
• Yamagishi M, Uchimaru K. Targeting EZH2 in cancer therapy. Curr. Opin. Oncol. 29(5), 375–381 (2017).
   PubMed Web of Science ®Google Scholar
• Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat. Med. 22(2), 128–134 (2016).
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419(6907), 624–629 (2002).
   PubMed Web of Science ®Google Scholar
• Cao Q, Yu J, Dhanasekaran SM et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27(58), 7274–7284 (2008).
   PubMed Web of Science ®Google Scholar
• Yu J, Yu J, Rhodes DR et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 67(22), 10657–10663 (2007).
   PubMed Web of Science ®Google Scholar
• Liu Q, Wang G, Li Q et al. Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer. Int. J. Cancer 145(2), 415–426 (2019).
   PubMed Web of Science ®Google Scholar
• Kim J, Lee Y, Lu X et al. Polycomb- and methylation-independent roles of EZH2 as a transcription activator. Cell Rep. 25(10), 2808–2820; e2804 (2018).
   PubMed Web of Science ®Google Scholar
• Xu K, Wu ZJ, Groner AC et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent. Science 338(6113), 1465–1469 (2012).
   PubMed Web of Science ®Google Scholar
• Dardenne E, Beltran H, Benelli M et al. N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell 30(4), 563–577 (2016).
   PubMed Web of Science ®Google Scholar
• Ku SY, Rosario S, Wang Y et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355(6320), 78–83 (2017).
   PubMed Web of Science ®Google Scholar
• Xiao L, Tien JC, Vo J et al. Epigenetic reprogramming with antisense oligonucleotides enhances the effectiveness of androgen receptor inhibition in castration-resistant prostate cancer. Cancer Res. 78(20), 5731–5740 (2018).
   PubMed Web of Science ®Google Scholar
• Pittoni P, Tripodo C, Piconese S et al. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res. 71(18), 5987–5997 (2011).
   PubMed Web of Science ®Google Scholar
• Sulsenti RFB, Bongiovanni L, Cancila V et al. Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma. Front. Immunol. 12, 622001 (2021).
   PubMed Web of Science ®Google Scholar
• Greenberg NM, Demayo F, Finegold MJ et al. Prostate cancer in a transgenic mouse. Proc. Natl Acad Sci. USA 92(8), 3439–3443 (1995).
   PubMed Web of Science ®Google Scholar
• Enriquez C, Cancila V, Ferri R et al. Castration-induced down-regulation of SPARC in stromal cells drives neuroendocrine differentiation of prostate cancer. Cancer Res. 81(16), 4257–4274 (2021).
   PubMed Web of Science ®Google Scholar
• Beltran H, Tomlins S, Aparicio A et al. Aggressive variants of castration-resistant prostate cancer. Clin. Cancer Res. 20(11), 2846–2850 (2014).
   PubMed Web of Science ®Google Scholar
• Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 73(2), 483–489 (2013).
   PubMed Web of Science ®Google Scholar
• Smith R, Liu M, Liby T et al. Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease. Sci. Rep. 10(1), 21750 (2020).
   PubMed Web of Science ®Google Scholar
• Masoodi KZ, Eisermann K, Yang Z et al. Inhibition of androgen receptor function and level in castration-resistant prostate cancer cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone. Endocrinology 158(10), 3152–3161 (2017).
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Yasukawa M, Lyons B et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor gamma chain(null) mice. Blood 106(5), 1565–1573 (2005).
   PubMed Web of Science ®Google Scholar
• Degl'innocenti E, Grioni M, Boni A et al. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur. J. Immunol. 35(1), 66–75 (2005).
   PubMed Web of Science ®Google Scholar
• Mylin LM, Bonneau RH, Lippolis JD, Tevethia SS. Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J. Virol. 69(11), 6665–6677 (1995).
   PubMed Web of Science ®Google Scholar
• Bhat P, Leggatt G, Waterhouse N, Frazer IH. Interferon-gamma derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death Dis. 8(6), e2836 (2017).
   PubMedGoogle Scholar
• Ross SH, Cantrell DA. Signaling and function of interleukin-2 in T lymphocytes. Annu. Rev. Immunol. 36, 411–433 (2018).
   PubMed Web of Science ®Google Scholar
• Mills KHG. IL-17 and IL-17-producing cells in protection versus pathology. Nat. Rev. Immunol. 23(1), 38–54 (2023).
   PubMed Web of Science ®Google Scholar
• Chen YT, Zhu F, Lin WR, Ying RB, Yang YP, Zeng LH. The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A. Cancer Chemother. Pharmacol. 77(4), 757–765 (2016).
   PubMed Web of Science ®Google Scholar
• Puca L, Bareja R, Prandi D et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat. Commun. 9(1), 2404 (2018).
   PubMedGoogle Scholar